AKTS — Aktis Oncology, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2035832 ·
Last close
$17.74
Market Cap
$953.47M
52W High
$34.19
52W Low
$14.72
ADV30
426,568
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 3,384,000 | — | — | -24,144,000 | 557,596,000 | 82,491,000 | 72,758,000 |
| Mar 2026 | 3,227,000 | — | -22,706,000 | -18,325,000 | 576,801,000 | 371,630,000 | 70,693,000 |
| Dec 2025 | 1,870,000 | — | -17,375,000 | -15,138,000 | 264,885,000 | 37,784,000 | 411,034,000 |
| Sep 2025 | — | — | — | — | 279,037,000 | 180,253,000 | 411,430,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-69,764,000
Investing CF
$-239,756,000
Financing CF
$334,503,000
CapEx
$-10,130,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.81
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-174,889,000
Inventory
—
Receivables
—
ST Investments
$166,854,000
EBIT TTM
$-73,859,000
Pretax Income TTM
$-60,504,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,060,000
EBITDA
$-84,359,000
Free Cash Flow
—
Enterprise Value
$789,854,336
Total Cash
$517,320,000
Total Debt
$11,240,000
Shares Out
53,746,670
Trailing EPS
$-1.32
Book Value
$8.76
ROE
—
ROA
—
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,497,000 | -74,684,000 | -63,731,000 | 264,885,000 | 411,034,000 | -146,149,000 | -64,127,000 |
| Dec 2024 | 1,487,000 | -52,050,000 | -43,980,000 | 326,181,000 | 413,984,000 | -87,803,000 | 14,762,000 |
| Dec 2023 | 0 | -34,794,000 | -28,641,000 | 122,355,000 | 168,661,000 | -46,306,000 | -30,004,000 |
| Dec 2022 | 0 | -19,764,000 | -17,929,000 | 138,322,000 | 157,552,000 | -19,230,000 | -18,125,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$576,801,000
Forward EPS
$-2.15
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $18.01 · call volume: 52 · put volume: 11Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SPTX | Seaport Therapeutics, Inc. | $958.73M | $17.91 | — |
| ANRO | Alto Neuroscience, Inc. | $942.99M | $24.03 | — |
| KURA | Kura Oncology, Inc. | $935.87M | $10.52 | — |
| LTGO | Latigo Biotherapeutics, Inc. | $980.57M | $14.79 | — |
| SVRA | Savara Inc | $992.37M | $4.83 | — |
News headlines (Yahoo Finance, 1h cache)
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
2026-10-01 12:00 · Yahoo
Aktis Oncology to Present at Upcoming September Investor Conferences
2026-09-09 12:00 · Yahoo
Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says
2026-08-19 15:42 · Yahoo
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
2026-08-13 20:01 · Yahoo
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
2026-05-27 20:05 · Yahoo
A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound
2026-05-25 19:05 · Yahoo
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company
2026-05-13 20:30 · Yahoo
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
2026-05-11 20:01 · Yahoo
Aktis Oncology to Present at the BofA Securities Health Care Conference
2026-05-06 12:00 · Yahoo
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
2026-04-16 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.